EP0739204A4 - Piperidines, pyrrolidines et hexahydro-1h-azepines favorisant la liberation de l'hormone de croissance - Google Patents

Piperidines, pyrrolidines et hexahydro-1h-azepines favorisant la liberation de l'hormone de croissance

Info

Publication number
EP0739204A4
EP0739204A4 EP95902467A EP95902467A EP0739204A4 EP 0739204 A4 EP0739204 A4 EP 0739204A4 EP 95902467 A EP95902467 A EP 95902467A EP 95902467 A EP95902467 A EP 95902467A EP 0739204 A4 EP0739204 A4 EP 0739204A4
Authority
EP
European Patent Office
Prior art keywords
alkyl
hydrogen
aryl
cycloalkyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95902467A
Other languages
German (de)
English (en)
Other versions
EP0739204A1 (fr
Inventor
Gregori J Morriello
Arthur A Patchett
Lihu Yang
Meng H Chen
Ravi Nargund
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/323,998 external-priority patent/US5492920A/en
Priority claimed from US08/323,994 external-priority patent/US5494919A/en
Priority claimed from US08/323,988 external-priority patent/US5492916A/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0739204A1 publication Critical patent/EP0739204A1/fr
Publication of EP0739204A4 publication Critical patent/EP0739204A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Definitions

  • Growth hormone which is secreted from the pituitary, stimulates growth of all tissues of the body that are capable of growing.
  • growth hormone is known to have the following basic effects on the metabolic processes of the body: (1) Increased rate of protein synthesis in all cells of the body; (2) Decreased rate of carbohydrate utilization in cells of the body; (3) Increased mobilization of free fatty acids and use of fatty acids for energy.
  • a deficiency in growth hormone secretion can result in various medical disorders, such as dwarf sm.
  • growth hormone Various ways are known to release growth hormone. For example, chemicals such as arginine, L-3,4-dihydroxyphenylalanine (L-DOPA), glucagon, vasopressin, and insulin induced hypoglycemia, as well as activities such as sleep and exercise, indirectly cause growth hormone to be released from the pituitary by acting in some fashion on the hypothalamus perhaps either to decrease somatostatin secretion or to increase the secretion of the known secretagogue growth hormone releasing factor (GRF) or an unknown endogenous growth hormone-releasing hormone or all of these.
  • L-DOPA L-3,4-dihydroxyphenylalanine
  • GRF growth hormone releasing factor
  • the problem was generally solved by providing exogenous growth hormone or by administering GRF or a peptidal compound which stimulated growth hormone production and/or release. In either case the peptidyl nature of the compound necessitated that it be administered by injection.
  • the source of growth hormone was the extraction of the pituitary glands of cadavers. This resulted in a very expensive product and carried with it the risk that a disease associated with the source of the pituitary gland could be transmitted to the recipient of the growth hormone.
  • Recombinant growth hormone has become available which, while no longer carrying any risk of disease transmission, is still a very expensive product which must be given by injection or by a nasal spray.
  • the instant invention is directed to certain piperidine, pyrrolidine, and hexahydro-lH-azepine compounds which have the ability to stimulate the release of natural or endogenous growth hormone.
  • the compounds thus have the ability to be used to treat conditions which require the stimulation of growth hormone production or secretion such as in humans with a deficiency of natural growth hormone or in animals used for food production where the stimulation of growth hormone will result in a larger, more productive animal.
  • a still further object is to describe the use of such compounds to increase the secretion of growth hormone in humans and animals.
  • a still further object of this invention is to describe compositions containing the piperidine, pyrrolidine, and hexahydro-lH-azepine compounds for the use of treating humans and animals so as to increase the level of growth hormone secretions. Further objects will become apparent from a reading of the following description.
  • R i is selected from the group consisting of:
  • Cl-ClO alkyl, aryl, aryl(Cl-C6 alkyl), (C3-C7 cycloalkyl)(Ci -C6 alkyl )- (C1-C5 alkyl)-K-(Cl-C5 alkyl)-, aryl(C ⁇ -C5 alkyl)-K-(Cl-C5 alkyl)-, and (C3-C7 cycloalkyl)(C ⁇ -C5 alkyl)-K-(Cl-C5 alkyl)-, where K is O, S(0)m, N(R2)C(0), C(0)N(R2), OC(O), C(0)0, -CR2 CR2-, or -C ⁇ C-.
  • aryl is selected from: phenyl, naphthyl, indolyl, azaindole, pyridyl, benzothienyl, benzofuranyl, thiazolyl, and benzimidazolyl. and R2 and alkyl may be further substituted by 1 to 9 halogen, S(0) m R2a- 1 - 4 _
  • OR2a or C(0)OR2a may be further substituted by 1 to 3 of Cl-C6 alkyl, 1 to 3 of halogen, 1 to 2 of OR2, methylenedioxy, -S(0) m R2, 1 to 2 of -CF3, -OCF3, nitro, -N(R2)C(0)(R2), -C(0)OR2, -C(0)N(R2)(R2), -lH-tetrazol-5-yl, -S ⁇ 2N(R2)(R2), -N(R2)S ⁇ 2 phenyl, or -N(R2)S02R2;
  • R2 is selected from: hydrogen, C1-C6 alkyl, and C3-C7 cycloalkyl, and where two C1-C6 alkyl groups are present on one atom, they may be optionally joined to form a C3-C8 cyclic ring, optionally including oxygen, sulfur or NR3a; R2a is hydrogen, or C1-C6 alkyl optionally substituted by hydroxyl;
  • R3 is selected from: hydrogen, -(CH2) r phenyl, -(CH2) r naphthyl, -C1-C10 alkyl, -C3-C7 cycloalkyl, where the phenyl, naphthyl and C3-C7 cycloalkyl rings may be substituted by 1 to 3 substituents selected from the group consisting of: C1-C6 alkyl, halogen, -OR2, -NHSO2CF3, -(CH2)rOR6, -(CH2) r N(R 2 )(R6), -(CH2)r (R ⁇ ), -(CH2)rC(0)OR2, -(CH2)rC(0)OR6, -(CH2)rOC(0)R2, -(CH2)rOC(0)R6, -(CH2)rC(0)R2, -(CH2)rC(0)R6, -(CH2)rC(0)N(R2)(R2), -(CH2)rC(0)N(R2)(R6),
  • R3a is hydrogen, or Cl-C6 alkyl optionally substituted by hydroxyl
  • W is selected from the group consisting of: hydrogen, -CN, -C(0)OR8, -C(0)OR2, -C(0)0(CH2)laryl, -C(0)N(R2)(R2); -C(0)N(R2)(R8), -C(0)N(R2)(CH2)1 aryl, -CH2N(R2)C(0)R8 -CH2N(R2)C(0)(CH2)iaryl, -(CH2) r OR2, -CH(OH)R2, -CH(OH)(CH2)laryl, -C(0)R2, -C(0)(CH2)l aryl, lH-tetrazol-5-yl, 5-amino-l, 2, 4-oxadiazol-3-yl, and 5-methyl-l, 2, 4-oxadiazol-3-yl, where R8 is hydrogen, Cl-C6 alkyl, or Cl-C6 alkyl substituted by 0R2, C(0)OR2, CON(R2)(R2), N(R2)C(0)R2, N(
  • X is selected from the group consisting of: hydrogen, -C ⁇ N,
  • (CH2)q and (CH2)t group may be optionally substimted by 1 to 2 C1-C4 alkyl, hydroxyl, C1-C4 lower alkoxy, carboxyl, CONH2, S(0) m CH3, carboxylate C1-C4 alkyl esters, or 1 H-tetrazol-5-yl
  • aryl is phenyl, naphthyl, pyridyl, thiazolyl, or lH-tetrazol-5-yl groups which may be optionally substimted by 1 to 3 halogen, 1 to 3 -OR2, -CON(R2)(R2), -C(0)OR2, 1 to 3 C1-C4 alkyl, -S(0) m R2, or lH-tetrazol-5-yl
  • Y is selected from the group consisting of: hydrogen, Cl-ClO alkyl, -(CH2)taryl, -(CH2)q(C3-C7 cycloalkyl),
  • R4 and R5 are independently hydrogen, C1-C6 alkyl, substituted Cl- C ⁇ alkyl where the substituents may be 1 to 5 halo, 1 to 3 hydroxy, 1 to 3 Cl-ClO alkanoyloxy, 1 to 3 C1 -C6 alkoxy, phenyl, phenoxy, 2- furyl, C 1-C6 alkoxycarbonyl, S(0) m (Cl-C6 alkyl); or R4 and R5 can be taken together to form -(CH2)d a (CH2)e- where L a is C(R2)2, O, S(0) m or N(R2), d and e are independently 1 to 3 and R2 is as defined above;
  • A is:
  • x and y are independently 0, 1, 2 or 3;
  • Z is N-R6a or O, where R6a is hydrogen or C1-C6 alkyl; R6 is hydrogen, C1-C6 alkyl, or (CH2)varyl, wherein the alkyl and (CH2)v groups may be optionally substituted by 1-2 0(R2), S(0) m R2- lH-tetrazol-5-yl, C(0)OR2, C(0)N(R2)(R2) or S ⁇ 2N(R2)(R2), N(R2)C(0)N(R2)(R2),and wherein aryl is phenyl, pyridyl, lH-tetrazol- 5-yl, triazolyl, imidazolyl, thiazolyl, pyrazolyl, thiadiazolyl, imidazolone- 1-yl, benzimidazol-2-yl, triazo none-yl optionally substimted with Cl- C6 alkyl, C3-C6 cycloalkyl, amino, or hydroxyl
  • R7 and R7a are independently hydrogen, C 1 -C6 alkyl, trifluoromethyl, phenyl, substituted C1-C6 alkyl where the substituents are imidazolyl, phenyl, indolyl, p-hydroxyphenyl, OR2, S(0) m R2, C(0)0(Cl-C6 alkyl), C3-C7 cycloalkyl, N(R2)(R2), C(0)N(R2)(R2); or R7 and R7a can independently be joined to one or both of R4 and R5 groups to form alkylene bridges between the terminal nitrogen and the alkyl portion of the R7 or R7a groups, wherein the bridge contains 1 to 5 carbons atoms; or R7 and R7a can be joined to one another to form a C3-C7 cycloalkyl;
  • n 1
  • a pyrrolidine ring is formed
  • n 2
  • a piperidine ring is formed
  • n 3
  • the ring is designated as a hexahydro-lH-azepine.
  • alkyl groups specified above are intended to include those alkyl groups of the designated length in either a straight or branched configuration which may optionally contain double or triple bonds.
  • exemplary of such alkyl groups are methyl (Me), ethyl (Et), propyl (Pr), isopropyl (i-Pr), butyl (Bu), sec-butyl (s-Bu), tertiary butyl (t-Bu), pentyl, isopentyl, hexyl, isohexyl, allyl, propinyl, butadienyl, hexenyl and the like.
  • alkoxy groups specified above are intended to include those alkoxy groups of the designated length in either a straight or branched configuration which may optionally contain double or triple bonds.
  • alkoxy groups are methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tertiary butoxy, pentoxy, isopentoxy, hexoxy, isohexoxy, allyloxy, propinyloxy, isobutenyloxy, hexenyloxy and the like.
  • halogen is intended to include the halogen atom fluorine, chlorine, bromine and iodine.
  • aryl within the present invention, unless otherwise specified, is intended to include aromatic rings, such as carbocychc and heterocyclic aromatic rings selected the group consisting of: phenyl, naphthyl, pyridyl, l-H-tetrazol-5-yl, thiazolyl, imidazolyl, indolyl, pyrimidinyl, thiadiazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiopheneyl, quinolinyl, pyrrazinyl, or isothiazolyl, which may be optionally substimted by 1 to 3 of Cl-C6 alkyl, 1 to 3 of halogen, 1 to 2 of -OR 2 , methylenedioxy, -S(0) m R2, 1 to 2 of -CF3, -OCF3, nitro, -N(R2)C(0)(R2), -C(0)OR2, -C(0)N(R2)(R2),
  • a first embodiment of the present invention is directed to the compounds of the structural formula Al:
  • R2 is selected from: hydrogen, C1-C6 alkyl, and C3-C7 cycloalkyl, and where two C1-C6 alkyl groups are present on one atom, they may be optionally joined to form a C3-C8 cyclic ring, optionally including oxygen, sulfur or NR3 a ;
  • R2a i hydrogen, or -C6 alkyl optionally substimted by hydroxyl
  • R3 is selected from: hydrogen, -(CH2) r phenyl, -(CH 2 ) r naphthyl. -C 1 -C 1 0 alkyl, -C3-C 7 cycloalkyl, where the phenyl, naphthyl and C3-C 7 cycloalkyl rings may be substituted by 1 to 3 substituents selected from the group consisting of: Cl-C6 alkyl, halogen, -OR2, -NHSO2CF3, -(CH2)rOR6, -(CH2) r N(R 2 )(R6), -(CH2)r (R ⁇ ), -(CH 2 ) r C(0)OR2, -(CH2)rC(0)OR6, -(CH2)rOC(0)R2, -(CH2)rOC(0)R6, -(CH2)rC(0)R2, -(CH2)rC(0)R6, -(CH2) r C(0)N(R2)(R2), -(CH2)rC(0)N
  • R3a is hydrogen, or C1-C6 alkyl optionally substituted by hydroxyl
  • W is selected from the group consisting of:
  • R8 is hydrogen, C 1-C6 alkyl, or C1-C6 alkyl substituted by OR2, C(0)OR2, CON(R2)(R2). N(R2)C(0)R2, N(R2)C(0)N(R2)(R2), and aryl is phenyl, pyridyl, or lH-tetrazol-5- yi;
  • X is selected from: hydrogen, -C ⁇ N, -(CH2)qN(R2)C(0)R2,
  • R4 and R5 are independently hydrogen, C1-C6 alkyl. substituted Cl- C ⁇ alkyl where the substituents may be 1 to 5 halo, 1 to 3 hydroxy, 1 to 3 Cl-ClO alkanoyloxy, 1 to 3 C1-C6 alkoxy, phenyl, phenoxy. 2- furyl, C1-C6 alkoxycarbonyl, S(0) m (C ⁇ -C6 alkyl); or R4 and R5 can be taken together to form -(CH2)dL a (CH2)e- where L a is C(R2)2, O, S(0)m or N(R2), d and e are independently 1 to 3 and R2 is as defined above;
  • A is:
  • x and y are independently 0, 1, 2 or 3;
  • Z is N-R6a or O, where R6a is hydrogen or C1-C6 alkyl
  • R6 is hydrogen, C1-C6 alkyl, or (CH2)varyl, wherein the alkyl and (CH2)v groups may be optionally substituted by 1-2 0(R2), S(0) m R2. lH-tetrazol-5-yl, C(0)OR2, C(0)N(R2)(R2) or S ⁇ 2N(R2)(R2), N(R2)C(0)N(R2)(R2),and wherein aryl is phenyl, pyridyl, lH-tetrazol- 5-yl, triazolyl, imidazolyl, thiazolyl, pyrazolyl, thiadiazolyl, imidazolone- 1-yl, benzimidazol-2-yl, triazoUnone-yl optionally substituted with Cl- C6 alkyl, C3-C6 cycloalkyl, amino, or hydroxyl;
  • R7 and R7a are independently hydrogen, C1-C6 alkyl, trifluoromethyl, phenyl, substituted Cl-C ⁇ alkyl where the substituents are imidazolyl, phenyl, indolyl, p-hydroxyphenyl, OR2, S(0) m R2, C(0)0(Cl-C6 alkyl).
  • C3-C7 cycloalkyl, N(R2)(R2), C(0)N(R2)(R2); or R7 and R7a can independently be joined to one or both of R4 and R5 groups to form alkylene bridges between the terminal nitrogen and the alkyl portion of the R7 or R7a groups, wherein the bridge contains 1 to 5 carbons atoms: or R7 and R7a can be joined to one another to form a C3-C7 cycloalkyl:
  • Rl is selected from the group consisting of:
  • R2 is hydrogen, C1-C6 alkyl, or C3-C7 cycloalkyl and where two C1-C6 alkyl groups are present on one atom they may be optionally joined to form a C4-C7 cyclic ring optionally including oxygen, sulfur or NR3 a ;
  • R3 is hydrogen or phenyl optionally substituted in the ortho position by a Cl-C6 alkyl group, -NHSO2CF3, -(CH2)r (lH-tetrazol-5-yl), -(CH2)rC(0)OR2, (CH )rC(0)N(R 2 )(R6);
  • R3a is hydrogen, or C1-C4 alkyl
  • W is -CN, -C(0)OR2, -C(0)N(R2)(R2), -C(0)N(R2)(CH2)1 phenyl, lH-tetrazol-5-yl, or -(CH2)rOR2;
  • X is hydrogen, -(CH2)qC(0)N(R2)(R6), or -(CH2)qC(0)OR2;
  • Y is hydrogen, Cl-C ⁇ alkyl, -(CH2)t phenyl, -(CH2)t pyridyl, or -(CH2)tthiazolyl;
  • R4 and R5 are independently hydrogen, C1-C6 alkyl, or substimted Cl- C6 alkyl where the substituents may be 1 to 5 halo, 1 to 3 hydroxyl, S(0)m (C1-C6 alkyl) or phenyl;
  • R6 is hydrogen, or C1-C6 alkyl
  • A is:
  • R7 and R7a are independently hydrogen -C6 alkyl, trifluoromethyl, phenyl, substituted C1-C6 alkyl where the substituents are imidazolyl, phenyl, indolyl, p-hydroxyphenyl, OR2, S(0)mR2, C(0)0(Cl-C6 alkyl).
  • C5-C7 cycloalkyl, N(R2)(R2), C(0)N(R2)(R2); or R7 and R7a can independently be joined to one of R4 or R5 to form alkylene bridges between the terminal nitrogen and the alkyl portion of R7 or R7 groups to form 5 or 6 membered rings; or R7 and R7 a can be joined to one another to form a C3 cycloalkyl; 1 is 0 or 1 ; n is 2; m is O, l, or 2; r is 0, 1, 2 or 3; q is 0 or 1 t is 0 or 1 ; and pharmaceutically acceptable salts and individual diastereomers thereof.
  • Rl is selected from the group consisting of: Cl-ClO alkyl, aryl (C1-C3 alkyl)-, and aryl (C0-C1 alkyl)-K-(Ci-C2 alkyl)-, where K is O or S(0)m and the aryl is phenyl, pyridyl, naphthyl, or indolyl which are optionally substituted by 1-2 C1-C4 alkyl, 1 to 2 halogen, 1 to 2 OR2, S(0) m R2 or C(0)OR2;
  • R2 is hydrogen, C1-C6 alkyl, or C3-C7 cycloalkyl and where two C 1-C6 alkyl groups are present on one atom they may be optionally joined to form a C5-C7 cyclic ring optionally including oxygen, sulfur or NR3 a ;
  • R3 is hydrogen or phenyl optionally substimted in the ortho position by a C1-C3 alkyl group, (CH2)r(lH-tetrazol-5-yl) or (CH2) r C(0)OR2;
  • R3a is hydrogen, or C1-C4 alkyl;
  • W is -CN, -C(0)OR2, or -C(0)N(R2)R2);
  • X is hydrogen or C(0)OR2
  • Y is hydrogen, benzyl, picoyl, or thiazolylmethyl
  • R4 and R5 are independently hydrogen, C1-C3 alkyl, substituted C1-C3 alkyl where the substituents may be 1 to 2 hydroxyl;
  • R7 and R7a are independently hydrogen or C1-C4 alkyl
  • Rl is selected from the group consisting of:
  • aryl is selected from: phenyl, naphthyl, indolyl, azaindole, pyridyl, benzothienyl, benzofuranyl, thiazolyl, and benzimidazolyl, and
  • R2 and alkyl may be further substimted by 1 to 9 halogen, S(0)mR2a. 1 to 3 of OR2a or C(0)OR2a. and aryl may be further substimted by 1 to 3 of C1-C6 alkyl, 1 to 3 of halogen, 1 to 2 of OR2, methylenedioxy, -S(0) m R2, 1 to 2 of -CF3, -OCF3, nitro, -N(R2)C(0)(R2), -C(0)OR2, -C(0)N(R2)(R2), -lH-tetrazol-5-yl, -S ⁇ 2N(R2)(R2), -N(R2)S02 phenyl, or -N(R2)S02R2;
  • R2 is selected from: hydrogen, C1-C6 alkyl, and C3-C7 cycloalkyl, and where two C1-C6 alkyl groups are present on one atom, they may be optionally joined to form a C3-C8 cyclic ring, optionally including oxygen, sulfur or NR3 a , where R3 a is hydrogen, or C1-C6 alkyl, optionally substituted by hydroxyl; R2a is hydrogen, or C1-C6 alkyl optionally substituted by hydroxyl;
  • R3 is selected from: -(CH2) r phenyl, -(CH2) r naphthyl, -C1-C10 alkyl, -C3-C7 cycloalkyl, and the phenyl, naphthyl and C3-C7 cycloalkyl rings may be substituted by 1 to 3 substituents selected from the group consisting of: C1-C6 alkyl, halogen, -OR2, -NHSO2CF3, -(CH2) r OR6, -(CH2)rN(R 2 )(R6), -(CH2)r (R ⁇ ), -(CH2) r C(0)OR2, -(CH2)rC(0)OR6, -(CH2)rOC(0)R2, -(CH2)rOC(0)R6, -(CH2)rC(0)R2, -(CH2)rC(0)R6, -(CH 2 )rC(0)N(R2)(R2), -(CH2) r C(0)N(R 2 )(
  • X is selected from: hydrogen, -C ⁇ N, -(CH2)qN(R2)C(0)R2,
  • A is:
  • x and y are independently 0, 1, 2 or 3;
  • Z is N-R6a or O, where R6a is hydrogen or C1-C6 alkyl
  • R6 is hydrogen, C1-C6 alkyl, or (CH2)varyl, wherein the alkyl and (CH2)v groups may be optionally substituted by 1-2 0(R2), S(0) m R2. lH-tetrazol-5-yl, C(0)OR2, C(0)N(R2)(R2) or S ⁇ 2N(R2)(R2), N(R2)C(0)N(R2)(R2),and wherein aryl is phenyl, pyridyl, lH-tetrazol- 5-yl, triazolyl, imidazolyl, thiazolyl, pyrazolyl, thiadiazolyl, imidazolone- 1-yl, oxadiazolyl, benzimidazol-2-yl, triazolinone-yl, optionally substituted with C1-C6 alkyl, C3-C6 cycloalkyl, amino, or hydroxyl;
  • R7 and R7a are independently hydrogen, C1-C6 alkyl, trifluoromethyl, phenyl, substituted C1-C6 alkyl where the substituents are imidazolyl, phenyl, indolyl, p-hydroxyphenyl, OR2, S(0) m R2, C(0)OR2, C3-C7 cycloalkyl, N(R2)(R2), C(0)N(R2)(R2); or R7 and R a can independently be joined to one or both of R4 and R5 groups to form alkylene bridges between the terminal nitrogen and the alkyl portion of the R7 or R7a groups, wherein the bridge contains 1 to 5 carbons atoms; or R7 and R7a can be joined to one another to form a C3-C7 cycloalkyl; m is 0, 1, or 2; n is 1, 2, or 3; q is O, 1, 2, 3 or 4; r is 0, 1, 2, or 3; t is O, 1, 2, or 3; v is
  • Rl is selected from the group consisting of:
  • R2 is hydrogen, C1-C6 alkyl, C3-C7 cycloalkyl and where two C1-C6 alkyl groups are present on one atom they may be optionally joined to form a C4-C7 cyclic ring optionally including oxygen, sulfur or NR3 a ;
  • R3 is phenyl which is optionally substituted by 1 to 2 Cl-C6 alkyl groups, 1 to 2 halogen, or 1 to 2 -OR2, and which may be further substimted in the ortho position by a substitutent selected from the group consisting of:
  • R3a is hydrogen, or C1-C4 alkyl
  • X is selected from: hydrogen, -(CH2)qN(R2)C(0)R2,
  • R2 group may be optionally substituted by hydroxyl, carboxyl, CONH2, S(0) m CH3, carboxylate Cl- C4 alkyl esters, or tetrazole and the aryl which is phenyl, naphthyl, pyridyl or 1-H-tetrazolyl may be optionally substituted by 1 to 2 halogen,
  • Y is selected from: hydrogen, Cl-C ⁇ alkyl, (CH2)taryl, -(CH2)q(C5-C6 cycloalkyl), -(CH2)q-K-(Cl-C6 alkyl), -(CH2)q-K-(CH2)ta ⁇ l, -(CH2)q-K-(CH2)t(C3-C7 cycloalkyl containing 0, NR2, or S), and -(CH2)q-K-(CH2)t (C5-C6 cycloalkyl), where K is O or S(0)m and where the alkyl groups may be optionally substituted by hydroxyl, carboxyl, CONH2, carboxylate C1 -C4 alkyl esters or lH-tetrazole-5-yl and the aryl which is phenyl, naphthyl, pyridyl, 1-H-tetrazolyl, thiazolyl, imidazolyl, pyrimidinyl
  • R4 and R5 are independently hydrogen, C1-C6 alkyl,or substituted Cl- C6 alkyl where the substituents may be 1 to 5 halo, 1 to 3 hydroxyl, S(0)m (C1-C6 alkyl) or phenyl;
  • R6 is H, C1-C6 alkyl, or (CH2)varyl, wherein the (CH2) V and alkyl groups may be optionally substimted by 1-2 0(R2), S(0) m R2, C(0)OR2, C(0)N(R2)(R2) or S ⁇ 2N(R2)(R2), N(R2)C(0)N(R2)(R2), wherein the aryl group could be phenyl, pyridyl, lH-tetrazol-5-yl, triazolyl, imidazolyl, thiazolyl, oxadiazolyl, pyrazolyl, thiadiazolyl, benzimidazol- 2-yl, optionally substituted with C1-C6 alkyl, C3-C6 cycloalkyl, amino, or hydroxyl;
  • A is: R 7
  • R7 and R7 a are independently hydrogen Cl-C6 alkyl, trifluoromethyl, phenyl, substituted Cl-C6 alkyl where the substituents are imidazolyl, phenyl, indolyl, p-hydroxyphenyl, OR2, S(0)mR2, C(0)OR2, C5-C7 cycloalkyl, N(R2)(R2), C(0)N(R2)(R2); or R7 and R7a can independently be joined to one of R4 or R5 to form alkylene bridges between the terminal nitrogen and the alkyl portion of R7 or R7a groups to form 5 or 6 membered rings; or R7 and R7 a can be joined to one another to form a C3 cycloalkyl;
  • Rl is selected from the group consisting of: Cl-ClO alkyl, aryl (C1 -C3 alkyl)-, (C3-C7 cycloalkyl)(C ⁇ -C3 alkyl)-, and aryl (C0-C1 alkyl)-K-(Cl-C2 alkyl)-, where K is O or S(0) m and aryl is specifically phenyl, pyridyl, naphthyl, indolyl, azaindolyl, or benzimidazolyl which is optionally substituted by 1-2 C1-C4 alkyl, 1 to 2 halogen, 1 to 2 OR2, S(0) m R2, or C(0)OR2;
  • R2 is hydrogen, C1-C6 alkyl, C3-C7 cycloalkyl and where two C1-C6 alkyl groups are present on one atom they may be optionally joined to form a C5-C7 cyclic ring optionally including oxygen, sulfur or NR3a;
  • R3 is phenyl optionally substituted by 1 to 2 C1-C6 alkyl groups, 1 to 2 halogen or 1 to 2 OR2, and which may be further substituted in the ortho position by a substitutent selected from the group consisting of: -NHSO2CF3, -(CH 2 )rOR6, -(CH ) r N(R 2 )(R6), -(CH2)r (R6), -(CH2)rC(0)OR6, -(CH2) r OC(0)R 2 , -(CH2) r OC(0)R6, -(CH 2 )rC(0)R2, -(CH 2 ) r C(0)R6, -(CH 2 ) r C(0)N(R2)(R2), -(CH2)rC(0)N(R2)(R6), -(CH 2 ) r N(R 2 )C(0)R2 -(CH 2 )rN(R 2 )C(0)R6, -(CH2)rN(R6)C(0)R2,
  • R3a is hydrogen, or C1-C4 alkyl
  • X is selected from: hydrogen, -(CH2)qN(R2)C(0)R2, -(CH2)qN(R2)C(0)(CH2)taryl, -(CH2)q N(R2)S02(CH2)ta ⁇ yl, -(CH2)q N(R2)S02R2, -(CH2)qN(R2)C(0)N(R2)(CH2)taryl,
  • R2 group may be optionally substimted by hydroxyl, carboxyl, -CONH2, -S(0)mCH3, carboxylate C1-C4 alkyl esters or tetrazole and aryl is phenyl, napthyl or pyridyl which may be further substituted by 1-2 halogen, 1 to 2 OR2, C(0)OR
  • Y is selected from: hydrogen, C1-C8 alkyl, (CH2)taryl, -(CH2)q C5-C7 cycloalkyl, -(CH2)q-K-(C ⁇ -C6 alkyl), --(CH2)q-K-(CH2)taryl, and -(CH2)q-K-(CH2)t (C5-C6 cycloalkyl), where K is S(0) m and where the alkyl groups may be optionally substituted by hydroxyl, carboxyl, CONH2, carboxylate C1-C4 alkyl esters or lH-tetrazole-5-yl and aryl is specifically phenyl, napthyl, pyridyl, thiazolyl, thiopheneyl, pyrazolyl, oxazolyl, isoxazolyl or imidazolyl which may be optionally substimted by 1 to 2 halogen, 1 to 2 OR2, 1 to 2 -N(R2)
  • R6 is hydrogen, C1-C6 alkyl or (CH2)varyl, wherein the C1-C6 alkyl and the (CH2)Varyl groups may be optionally substituted by 1-2 0(R2), S(0) m R2, C(0)OR2, C(0)N(R 2 )(R2) or S ⁇ 2N(R )(R2), N(R2)C(0)N(R2)(R2), wherein aryl is specifically phenyl, pyridyl, 1H- tetrazol-5-yl, triazolyl, imidazolyl, thiazolyl, oxadiazolyl, pyrazolyl, thiadiazolyl, benzimidazol-2-yl, optionally substituted with C1-C6 alkyl, C3-C6 cycloalkyl, amino, or hydroxyl;
  • R7 and R7a are independently hydrogen, C1-C2 alkyl, phenyl, substituted C1-C6 alkyl wherein the substitutent is imidazolyl, phenyl, indolyl, p- hydroxyphenyl, OR2, S(0)mR2; or R7 and R ⁇ a can be independently be joined to one another to form a C3 cycloalkyl;
  • Rl is selected from the group consisting of:
  • R2 is hydrogen, Cl-C6 alkyl, or C3-C7 cycloalkyl and where two C1-C6 alkyl groups are present on one atom they may be optionally joined to form a C5-C7 cyclic ring optionally including oxygen, sulfur or NR3a;
  • R3 is phenyl optionally substituted in the ortho position with a substitutent selected from the group consisting of: -NHSO2CF3, -(CH2) r OR6, -(CH2)r 0*6), -(CH2) r C(0)OR2, -(CH2)rC(0)OR6, -(CH2)rOC(0)R2, -(CH2)rOC(0)R6, -(CH2)rC(0)R2, -(CH2)rC(0)R6, -(CH2)rC(0)N(R2)(R2), -(CH2)rC(0)N(R2)(R6), -(CH2) r N(R 2 )C(0)R2 -(CH2) r N(R2)C(0)R6, -(CH2)rN(R6)C(0)R 2 , -(CH2) r N(R6)C(0)R6, -(CH2)rN(R6)C(0)R 2 , -(CH2) r N(R6)C(0)R6, -(CH2)rN(R6)C
  • R3a is hydrogen, or C1-C4 alkyl
  • X is selected from the group consisting of: hydrogen,
  • Y is selected from the group consisting of: hydrogen, Ci-C ⁇ alkyl, (CH2)taryl, -(CH2)q C5-C7 cycloalkyl, -(CH2)q- K-(Cl-C6 alkyl), -(CH2)q-K-(CH2) t aryl, or -(CH2)q-K-(CH2)t (C5-C6 cycloalkyl) where K is S(0)m and where the alkyl groups may be optionally substituted by hydroxyl, carboxyl, CONH2, carboxylate Cl- C4 alkyl esters or lH-tetrazole-5-yl, and where aryl is specifically phenyl, naphthyl, pyridyl, thiazolyl, thiopheneyl, pyrazolyl, oxazolyl, isoxazolyl, thiadiazolyl, pyrimidinyl, or imidazolyl, which may be optionally subs
  • A is selected from the group consisting of:
  • R4 and R5 are independently selected from the group consisting of:
  • R6 is hydrogen, C1-C6 alkyl or (CH2)varyl wherein the alkyl and (CH2)v groups may be optionally substimted by halogen, OR2, N(R2)(R2), C3-C6 cycloalkyl, lH-tetrazol-5-yl, C(0)OR2,
  • aromatic groups are optionally substituted with C1-C2 alkyl, -N(R2)(R2). or hydroxy ;
  • All of the still more preferred compounds shown above have at least one asymmetric center. Additional asymmetric centers may be present on the molecule depending upon the nature of the substituents on the piperidine ring. Each such asymmetric center will produce two optical isomers and it is intended that all such optical isomers, as separated, pure or partially purified optical isomers, racemic mixtures or diastereomeric mixtures thereof, be included within the ambit of the present invention.
  • R2 is selected from: hydrogen, C1-C6 alkyl, and C3-C7 cycloalkyl, and where two C1-C6 alkyl groups are present on one atom, they may be optionally joined to form a C3-C8 cyclic ring, optionally including oxygen, sulfur or NR3 a , where R3 a is hydrogen, or C1-C6 alkyl, optionally substituted by hydroxyl; R2a is hydrogen, or C1-C6 alkyl optionally substituted by hydroxyl; X is selected from: hydrogen, -C ⁇ N, -(CH2)qN(R2)C(0)R2,
  • R4 and R5 are independently hydrogen, C1-C6 alkyl, or substituted Ci- C6 alkyl where the substiments may be 1 to 5 halo, 1 to 3 hydroxy, 1 to 3 Cl-ClO alkanoyloxy, 1 to 3 Cl-C6 alkoxy, phenyl, phenyloxy, 2-furyl, C1-C6 alkoxycarbonyl, S(0) m (Cl-C6 alkyl), or R4 and R5 may be taken together to form -(CH2)d-L a (CH2) e - where L a is -C(R2)2-, O, S(0) m or N(R2), d and e are independently 1 to 3 and R2 is as defined above;
  • A is:
  • x and y are independently 0, 1, 2 or 3;
  • Z is N-R6a or O, where R6a is hydrogen or C1-C6 alkyl
  • R7 and R7a are independently hydrogen, C1-C6 alkyl, trifluoromethyl, phenyl, or substimted C1-C6 alkyl where the substiments are imidazolyl, phenyl, indolyl, p-hydroxyphenyl, OR2, S(0) m R2, C(0)OR2, C3-C7 cycloalkyl, N(R2)(R2), C(0)N(R2)(R2), or R7 and R7 a may independently be joined to one or both of R4 and R5 groups to form an alkylene bridge between the terminal nitrogen and the alkyl portion of the R7 or R7a groups, wherein the bridge contains 1 to 5 carbons atoms, or R7 and R7a can be joined to one another to form C3-C7 cycloalkyl;
  • n 0, 1, or 2
  • n 1, 2, or 3
  • q 0, 1, 2, 3, or 4
  • t 0, 1, 2, or 3
  • pharmaceutically acceptable salts and individual diastereomers thereof Preferred compounds within this third embodiment include those of Formula Cla:
  • Rl is selected from the group consisting of:
  • R2 is hydrogen, C1-C6 alkyl, or C3-C7 cycloalkyl, and where two C1-C6 alkyl groups are present on one atom they may be optionally joined to form a C4-C7 cyclic ring optionally including oxygen, sulfur or NR3 a ;
  • R3a is hydrogen, or C1-C4 alkyl
  • X is selected from: hydrogen, -(CH2)qN(R2)C(0)R2, -(CH2)qN(R2)C(0)(CH2)taryl, -(CH2)qN(R 2 )C(0)OR2, -(CH2)qN(R2)S ⁇ 2(CH2)taryl, -(CH2)qN(R2)S ⁇ 2R2,
  • R2 group may be optionally substituted by hydroxyl, carboxyl, CONH2, S(0) m CH3, carboxylate Cl- C4 alkyl esters, or tetrazole
  • aryl is phenyl, naphthyl, pyridyl or 1-H- tetrazolyl which may be optionally substituted by 1 to 2 halogen, 1 to 2 -OR2, -CONH2, -C(0)OR2, 1 to 3 C1-C4 alkyl, -S(0) m R2, or 1H- tetrazole-5-yl;
  • Y is selected from: hydrogen, C1-C8 alkyl, (CH2)taryl, -(CH2)q(C5-C6 cycloalkyl), -(CH2)q-K-(Cl-C6 alkyl), -(CH2)q-K-(CH2)taryl, -(CH2)q-K-(CH2)t(C3-C7 cycloalkyl containing O, NR2, or S), and -(CH2)q-K-(CH2)t (C5-C6 cycloalkyl), where K is O or S(0)m and where the alkyl groups may be optionally substituted by hydroxyl, carboxyl, CONH2, carboxylate C1-C4 alkyl esters or lH-tetrazole-5-yl and aryl is phenyl, naphthyl, pyridyl, 1-H-tetrazolyl, thiazolyl, imidazolyl, indolyl, pyrimi
  • R4 and R5 are independently hydrogen, C1-C6 alkyl, or substituted Cl- C6 alkyl where the substituents may be 1 to 5 halo, 1 to 3 hydroxyl, S(0)m (C1-C6 alkyl) or phenyl;
  • A is:
  • R 7a where x is 0, or 1 ;
  • R7 and R7a are independently hydrogen C1-C6 alkyl, trifluoromethyl, phenyl, substituted C1-C6 alkyl where the substituents are imidazolyl, phenyl, indolyl, p-hydroxyphenyl, OR2, S(0)mR2, C(0)OR2, C5-C7 cycloalkyl, -N(R2)(R2), -C(0)N(R2)(R2); or R7 and R7 a can independently be joined to one of R4 or R5 to form alkylene bridges between the terminal nitrogen and the alkyl portion of R7 or R7a groups to form 5 or 6 membered rings; or R7 and R7a can be joined to one another to form a C3 cycloalkyl;
  • Rl is selected from the group consisting of: Cl-ClO alkyl, aryl (C1-C3 alkyl)-, (C3-C7 cycloalkyl)(Cl-C3 alkyl)-, and aryl (Q)-Cl alkyl)-K-(Cl-C2 alkyl)-, where K is O or S(0) m and the aryl is phenyl, pyridyl, naphthyl, indolyl, azaindolyl, or benzimidazolyl which is optionally substimted by 1-2 C1-C4 alkyl, 1 to 2 halogen, 1 to 2 OR2, S(0) m R2, or C(0)OR2; R2 is hydrogen, C1-C6 alkyl, or C3-C7 cycloalkyl, and where two C1-C6 alkyl groups are present on one atom they may be optionally joined to form a C5-C7 cyclic ring optional
  • R3a is hydrogen, or C1-C4 alkyl
  • X is selected from: hydrogen, -(CH2)qN(R2)C(0)R2, -(CH2)qN(R2)C(0)(CH2)taryl, -(CH2)q N(R2)S02(CH2) t aryl, -(CH2)q N(R2)S02R2, -(CH2)qN(R2)C(0)N(R2)(CH2)taryl, -(CH2)qN(R2)C(0)N(R2)(R2), -(CH2)qC(0)N(R 2 )(R2), -(CH 2 )qN(R2)C(0)OR2, -(CH2)qC(0)N(R2)(CH2)taryl, -(CH2)qC(0)OR2, -(CH2)qC(0)0(CH2)taryl, -(CH2)qOC(0)R2, -(CH2)qOC(0)(CH2)taryl, -(CH2)qS(0) m R2, and -(CH2)qS(0) m (CH2)taryl, where
  • Y is selected from: hydrogen, Cl-C ⁇ alkyl, (CH2)taryl, -(CH2)q C5-C7 cycloalkyl, -(CH2)q-K-(Cl-C6 alkyl), -(CH2)q-K-(CH2)taryl, and -(CH2)q-K-(CH2)t (C5-C6 cycloalkyl), where K is S(0) m and where the alkyl groups may be optionally substituted by hydroxyl, carboxyl, CONH2, carboxylate C1-C4 alkyl esters or lH-tetrazole-5-yl and aryl is phenyl, napthyl, pyridyl, thiazolyl, thiopheneyl, pyrazolyl, oxazolyl, isoxazolyl or imidazolyl which may be optionally substituted by 1 to 2 halogen, 1 to 2 OR2, 1 to 2 -N(R2)(R2)
  • R4 and R5 are independently hydrogen, C1-C4 alkyl, or substituted Cl- C3 alkyl where the substiments may be 1 to 2 hydroxyl;
  • A is R *7
  • R7 and R7a are independently hydrogen, Cl-C6 alkyl, phenyl, substituted Cl-C6 alky wherein the substitutent is imidixolyl, phenyl, indolyl, p- hydroxyphenyl, OR2, S(0)mR2, or R7 and R7 a may be joined to one another to form a C3 cycloalkyl;
  • m is O, l, or 2; q is 0, 1, 2, or 3; t is O, 1, 2, or 3; and pharmaceutically acceptable salts and individual diastereomers thereof.
  • Rl is selected from the group consisting of:
  • X is selected from the group consisting of: hydrogen,
  • Y is selected from the group consisting of: hydrogen, or their regioisomers whereof where not specified, with the proviso that if X is hydrogen, Y is other than hydrogen;
  • A is selected from the group consisting of:
  • R4 and R5 are independently selected from the group consisting of:
  • the compounds of the instant invention all have at least one asymmetric center as noted by the asterisk in the structural Formula I above. Additional asymmetric centers may be present on the molecule depending upon the nature of the various substituents on the molecule. Each such asymmetric center will produce two optical isomers and it is intended that all such optical isomers, as separated, pure or partially purified optical isomers, racemic mixtures or diastereomeric mixtures thereof, be included within the ambit of the instant invention.
  • the asymmetric center represented by the asterisk in Formula I it has been found that the absolute stereochemistry of the more active and thus more preferred isomer is as shown in Formula II.
  • the W group may also be present in either R- or S- configurations. Both afford active growth hormone secretagogues although, in general, the R- configuration is more active.
  • the W group may be cis- or trans- in respect to substituents X, Y or R3. In the case of the asymmetric center which bears the X and Y groups, in most cases, both the R- and S- configurations are consistent with useful levels of growth hormone secretagogue activity.
  • configurations of many of the most preferred compounds of this invention are indicated.
  • the W, X and Y groups may also be ris- or trans- to the R3 substituent. In some of the most preferred compounds a cis- or trans- relationship is also specified in respect to the R3 substitutent.
  • the instant compounds are generally isolated in the form of their pharmaceutically acceptable acid addition salts, such as the salts derived from using inorganic and organic acids.
  • acids are hydrochloric, nitric, sulfuric, phosphoric, formic, acetic, trifluoroacetic, propionic, maleic, succinic, malonic, methane sulfonic and the like.
  • certain compounds containing an acidic function such as a carboxy can be isolated in the form of their inorganic salt in which the counterion can be selected from sodium, potassium, lithium, calcium, magnesium and the like, as well as from organic bases.
  • the preparation of compounds of Formula I of the present invention can be carried out in sequential or convergent synthetic routes. Syntheses detailing the preparation of the compounds of Formula I in a sequential manner are presented in the following reaction schemes.
  • the phrase standard peptide coupling reaction conditions is used repeatedly here, and it means coupling a carboxylic acid with an amine using an acid activating agent such as EDC, DCC, and BOP in a inert solvent such as dichloromethane in the presence of a catalyst such as HOBT.
  • an acid activating agent such as EDC, DCC, and BOP
  • a inert solvent such as dichloromethane
  • HOBT a catalyst
  • protective groups for amine and carboxylic acid to facilitate the desired reaction and minimize the undesired reaction are well documented. Conditions required to remove protecting groups which may be present and can be found in Greene, T; Wuts, P. G. M. Protective Groups in Organic Synthesis , John Wiley & Sons, Inc., New York, NY 1991. CBZ and BOC were used extensively in the synthesis, and their removal conditions are known to those skilled in the art.
  • Removal of CBZ groups can be achieved by a number of methods known in the art; for example, catalytic hydrogenation with hydrogen in the presence of a nobel metal or its oxide such as palladium on activated carbon in a protic solvent such as ethanol.
  • removal of CBZ groups can also be achieved by treatment with a solution of hydrogen bromide in acetic acid, or by treatment with a mixture of TFA and dimethylsulfide.
  • Removal of BOC protecting groups is carried out in a solvent such as methylene chloride or methanol or ethyl acetate, with a strong acid, such as trifluoroacetic acid or hydrochloric acid or hydrogen chloride gas.
  • the protected amino acid derivatives 1 are, in many cases, commercially available, where the protecting group L is, for example, BOC or CBZ groups.
  • Other protected amino acid derivatives 1 can be prepared by literature methods (Williams, R. M. Synthesis of Optically Active ⁇ - Amino Acids. Pergamon Press: Oxford, 1989).
  • Many of the piperidines, pyrrolidines and hexahydro-lH-azepines of formula 2 are either commercially available or known in the literature and others can be prepared following literature methods desribed for known compounds, some of which are described here.
  • the skills required in carrying out the reaction and purification of the resulting reaction products are known to those skilled in the art. Purification procedures includes crystallization, and normal phase or reverse phase chromatography.
  • the compounds of general formula I of the present invention may also be prepared in a convergent manner as described in Reaction Schemes 6, 7 and 8.
  • Other ester protected amino acids can be prepared by classical methods familiar to those skilled in the art. Some of these methods include the reaction of the amino acid with an alcohol in the presence of an acid such as hydrochloric acid or p-toluenesulfonic acid and azeotropic removal of water. Other methods includes the reaction of a protected amino acid with a diazoalkane, or with an alcohol and an acid activating agent such as EDC, DCC in the presence of a catalyst such as DMAP and removal of the protecting group L.
  • Conversion of the ester 11 or 11a to intermediate acids 12 or 12a can be achieved by a number of methods known in the art as described in Scheme 7; for example, methyl and ethyl esters can be hydrolyzed with lithium hydroxide in a protic solvent like aqueous methanol.
  • removal of benzyl groups can be accomplished by a number of reductive methods including hydrogenation in the presence of palladium catalyst in a protic solvent such as methanol.
  • An allyl ester can be cleaved with tetrakis-triphenylphosphine palladium catalyst in the presence of 2-ethylhexanoic acid in a variety of solvents including ethyl acetate and dichloromethane (see J. Org. Chem.. 42. 587 (1982)).
  • Acid 12 or 12a can then be elaborated to I or compound 7 as described in Scheme 8.
  • Coupling of piperidines, pyrrolidines or hexahydro-lH-azepines of formula 2 to acids of formula 12 or 12a, wherein L is a suitable protecting group is conveniently carried out under the standard peptide coupling reaction conditions. Transformation of 7 to I is achieved by removal of the protecting group L.
  • R4 and/or R5 is H, substituted alkyl groups may be optionally added to the nitrogen atom as described in Scheme 4.
  • the 2-substituted piperidines, pyrrolidines or hexahydro-lH- azapines are either commercially available or can be prepared by literature procedures. Illustrated herein are some, but by no means all, the methods for their preparation.
  • X and Y are not both hydrogen and/or n is not 2, regioisomers and diastereoisomers may arise, and they may be separated by chromatography methods.
  • Hydrolysis of the amino nitrile under acidic or basic conditions yields the amino acid.
  • the hydroxylaminonitrile can be hydrolyzed first, then reduced by palladium catalyzed hydrogenation to afford the amino acid of formula A15.
  • the amino acid and their derivatives prepared according to this method are racemic.
  • the nitrile A2a can be prepared by oxidation of the compound A13 to the imine as described in the literature (Goti and Romani in Tetrahedron Letters. 35. 6567-6570 (1994)) followed by reaction with cyanide.
  • W can also be introduced by direct alkylation of the Boc protected compound A13 by butyl lithium followed by addition of electrophiles known as the Beak alkylation (Beak and Lee J. Org. Chem. , 55, 2578-2580 (1990)).
  • Asymmetric introduction of W can also be achieved by using a chiral catalyst (Kerrick and Beak, J. Am. Chem. Soc, 113, 9708-9710 (1991)).
  • the carboxylic acid functionality at the 2-position of compounds of formula A15 can be converted to ester, amide, nitrile, acyl sulfonamide, and moieties as defined by W to give compound of general formula 2 according to the conventional methods well documented in the literature and known to those skilled in the art (The Practice of Peptide Synthesis, by M. Bodanszky and A. Bodanszky, Springer- Verlag, 1984).
  • L is an appropriate protecting group such as BOC, CBZ, etc.
  • the carboxylic acid can also be converted into its next higher homologue, or to a derivative of the homologous acid, such as amide or ester by an Arndt-Eistert reaction.
  • ester can be directly homologated by the protocol using ynolate anions described by C. J. Kowalski and R. E. Reddy in J. Org. Chem.. 57, 7194-7208 (1992).
  • the resulting acid and/or ester can be converted to the next higher homologue, and so on and so forth.
  • Illustrated in Scheme Al 1 is a general method to introduce Y wherein X is an electron withdrawing group such as -CN, -CO2R8, where R8 is alkyl, aryl, and alkyl(Cl-C4)aryl are either known compounds or may be prepared by methods described above or by methods analogous to those used for the preparation of known compounds.
  • X is an electron withdrawing group such as -CN, -CO2R8, where R8 is alkyl, aryl, and alkyl(Cl-C4)aryl are either known compounds or may be prepared by methods described above or by methods analogous to those used for the preparation of known compounds.
  • Y substitution can be achieved by first reacting compounds of formula A18 with a strong base such as potassium bis(trimethylsilyl)amide, lithium diisopropylamide following by addition of alkylating reagents such as alkyl halides, aryl alkyl halides, acyl halides, and haloformates in a inert solvent such as THF at temperatures from -100° to room temperature.
  • alkylating reagents such as alkyl halides, aryl alkyl halides, acyl halides, and haloformates in a inert solvent such as THF at temperatures from -100° to room temperature.
  • Thio derivatives where the sulfur is attached directly to an alkyl or an aryl group can be prepared similarly by reacting with a disulfide.
  • the halides used in these reactions are either commercially available or known compounds in the literature can be prepared by methods analogous to those used for the preparation of known compounds.
  • racemic piperidine, pyrrolidine and hexahydro-lH-azepine derivatives can be converted directly to growth hormone secretagogues or their intermediates, and the resulting diastereomeric mixtures can be separated at the appropriate stage by chromatography to yield the enantiomerically pure compounds.
  • asymmetric synthesis can be carried out to synthesize optically pure piperidine, pyrrolidine and hexahydro-lH- azepine derivatives.
  • optically active piperidine-2- carboxylic acid derivatives A 15a, A 15b can be prepared by the aza-Diels- Alder reaction as described by Bailey et al (J. Chem. Soc. Perkin Trans I. 1337-1340 (1991)). Reaction between the chiral imine A23 and the diene A24 in the presence of TFA (1 equivalent) and water (catalytic) gives the adducts A25 and A26 with good diastereoselectivity.
  • the two diastereoisomers can be separated, and each can be hydrogenated to reduce the double bond and to remove the chiral auxiliary. All four possible isomers can be achieved by this methodology. Illustrated here (Scheme A13) is the preparation of the two isomers A15a and A15b which have an S-configuration at the chiral center adjacent to the COOH. The two R- isomers at this center can be prepared similarly using compound A26. SCHEME B9
  • the 3,4-disubstituted piperidines, pyrrolidines and hexahydro-lH-azepines of formula B21 wherein X is an electron withdrawing group like an ester, ketone, nitrile, etc., can be further alkylated, hydroxylated, halogenated by using methods familiar to those skilled in the art.
  • deprotection of the protecting group L can be carried out by methods familiar to those skilled in the art.
  • the piperidine B27 can be elaborated to compounds of Formula I by using chemistry detailed in Schemes 1-8.
  • the acid intermediate B28 can be used to prepare compounds bearing a variety of highly functionalized piperidines that can be transformed to compoundsof formula I.
  • the piperidine B26 may also serve as a key intermediate for the synthesis of a variety of piperidines of formula B22a, wherein Rio may be alkyl and aryl amides, alkyl and aryl acylsulfonamides, alkyl and aryl ureas, alkyl and aryl carbamates, etc.
  • the piperidine nitrogen of B26 can be protected with a protecting group L (commonly used groups include BOC, CBZ, FMOC) by well documented methods and the ester unit can now be hydrolyzed with sodium or potassium hydroxide in aqueous or alcoholic media to give B29.
  • the protecting group L can be removed and elaborated to compounds of Formula I using chemistry presented in Schemes 1-8.
  • the protecting group L may be removed and elaborated to compounds of formula I by using chemistry detailed in Schemes 1-8.
  • heterocycle bearing piperidines of formula B32 can also be prepared from intermediate B31 as shown in Scheme B16.
  • Addition of formyl hydrazine to B33 followed by heating of the intermediate in an inert solvent like toluene provides a piperidine of formula B32, wherein X, Y H and Rl 1 is a 1,2,4-triazole.
  • acids, acid chlorides, nitriles, and imino-ethers serve as key intermediates in the preparation of a number of other alkyl, phenyl, hydroxy, and amino-substituted heterocycles.
  • Many of the methods are documented in A.R. Katrizky, Handbook of Heterocyclic Chemistrv. Pergamon Press, 1985, New York, New York, and may be used to synthesize a variety of heterocycle bearing compounds.
  • the cis 3,4-disubstituted piperidines B38 can be converted to trans 3,4-disubstituted piperidines B40 as shown in Scheme B 19 by treating B38 with a catalytic amount of base such as sodium ethoxide in protic solvent.
  • a catalytic amount of base such as sodium ethoxide in protic solvent.
  • the ester functional group of B40 can be further modified by methods familiar to those skilled in the art, including the procedures described in Scheme B18.
  • the protecting group L from compounds of formulas B39 and B41 can be removed through conventional chemistry and elaborated to compounds of formula I by using chemistry described above.
  • cis 3,4-disubstituted piperidines of formula B43 can be prepared by the addition of B42 to ethyl nicotinate by the procedure of G.T. Borrett (U.S. Patent No. 4,861,893).
  • the acetal protecting group can be removed by a number of methods familiar to those skilled in the art.
  • the resulting aldehyde B44 serves as a key intermediate for the synthesis of highly functionalized 3,4-disubstituted piperidines.
  • the aldehyde B44 can be oxidized to the corresponding carboxylic acid B45 and then further elaborated to a variety of functional groups such as amides, ureas, carbamates, acylsulfonamides and etc. Some examples of these transformations are discussed in connection with Scheme B14. SCHEME B21
  • Compound B44 can also be converted to an ⁇ , ⁇ - unsamrated ester or nitrile by an Emmons reaction.
  • the resulting unsamrated ester or nitrile can be hydrogenated using a catalytic amount of palladium or platinum under hydrogen atmosphere.
  • the 3,4-disubstituted compounds 2 generated by these synthetic protocols are racemic.
  • Mono and disubstituted pyrrolidines and hexahydro-lH-azepines 2 generated by these synthetic protocols are also racemic.
  • Chiral intermediates of formula 2 are available by numerous methods including by the classical resolution of racemates. For example resolution can be achieved by the formation of diastereomeric salts of racemic amines with optically active acids such as D- and L- tartaric acid.
  • the determination of the absolute stereochemistry can be accomplished in a number of ways including X-ray crystallography of a suitable crystalline derivative such as a D- or L- tartaric acid salt. Alternatively, asymmetric synthesis can be carried out to synthesize optically pure compounds.
  • racemic intermediates of formula 2 can be derivatized with chiral reagents and these products may be separated by chromatography and chiral compounds of formula 2 may be regenerated from them by hydrolysis, or as stated earlier, racemic intermediates of formula 2 can be converted directly to growth hormone secretagogues, and the resulting diastereomeric mixtures can be separated by chromatography to yield the enantiomerically pure compounds.
  • 3-Monosubstituted piperidines of formula C13 can be prepared by the reduction of pyridine derivatives or their salts by hydrogenation in a suitable organic solvent such as water, acetic acid, alcohol, e.g. ethanol, or their mixture, in the presence of a noble metal catalyst such as platinum or an oxide thereof on a support such as activated carbon, and conveniently at room temperature and atmospheric pressure or under elevated temperature and pressure.
  • a noble metal catalyst such as platinum or an oxide thereof on a support such as activated carbon
  • 3-Monosubstituted pyrrolidines are commercially available or can be conveniently prepared by literature procedures. Shown in Scheme C9A is an example of the preparation of these compounds via pyrrolidine-3-carboxylic acid ester.
  • the commercially available compound methyl l-benzyl-4-oxo-3-pyrrolidinecarboxylate is reduced by borane (J. Chem. Soc. 24, 1618-1619). Removal of the benzyl group by catalytic hydrogenolysis followed by ester exchange in an appropriate alcohol medium such as ethyl alcohol in the presence of acid gave the compound C 13b.
  • the ester functionality may be further modified through conventional chemistry to other groups as defined by X.
  • 3-Monosubstituted pyrrolidines may also be prepared by catalytic hydrogenation of 3-substituted pyrroles.
  • Hexahydro-lH-azepines are commercially available or may be prepared by the literature procedure.
  • Hexahydro-lH-azepine-3- carboxylic acid (Krogsgaard-Larsen, P. et al., Acta. Chem. Scand.. B32. 327, (1978)) is esterified in an alcohol solvent in the presence of acid.
  • the ester functionality may be further modified through conventional chemistry to other groups within the definition of X.
  • Y substitution can be achieved by first reacting compounds of Formula C14 with a strong base such as lithium bis(trimethylsilyl)amide, lithium diisopropylamide following by addition of alkylating or acylating reagents such as alkyl halides, aryl alkyl halides, acyl halides, and haloformates in a inert solvent such as THF at temperatures from -100° to room temperature.
  • Thio derivatives where the sulfur is attached directly to an alkyl or an aryl group can be prepared similarly by reacting with a disulfide.
  • the halides used in these reactions are either commercially available or known compounds in the literature or may be prepared by methods analogous to those used for the preparation of known compounds.
  • the protecting group L in compounds of formula C15 may be removed with conventional chemistry to give compounds of Formula 2.
  • the cyanoacetates of general formula C16 may be alkylated with an ethoxycarbonylalkyl bromide or reacted with ethyl acrylate to give compounds of Formula C18.
  • Reduction of the nitriles C18 by borane or by hydrogenation using Raney Ni as a catalyst gives the corresponding primary amines, which upon refluxing in ethanol gives lactam C19.
  • Reduction of the lactam C19 by borane gives compounds of Formula C2a.
  • a malonate of general formula C20 may be alkylated with cyanoalkyl bromide or can be reacted with acrylonitrile to form compounds of formula C21.
  • Reduction of the nitriles C21 by borane or by hydrogenation using Raney Ni as a catalyst gives the corresponding primary amines, which upon refluxing in ethanol gives lactam C22.
  • Reduction of the lactam C22 by borane gives compounds of formula C2a.
  • the X, Y functionalities in compounds of general structure C15 may be further elaborated to groups not accessible by direct alkylation.
  • the ester (provided that this is the only ester group in the molecule) can be saponified to the carboxylic acid, which can be further derivatized to amides or other esters.
  • the carboxylic acid can be converted into its next higher homologue, or to a derivative of the homologous acid, such as amide or ester by an Arndt-Eistert reaction.
  • the ester can be directly homologated by the protocol using ynolate anions described by C. J. Kowalski and R. E. Reddy in J. Org. Chem.. 57, 7194-7208 (1992).
  • the resulting acid and/or ester may be converted to the next higher homologue, and so on and so forth.
  • the protecting group L may be removed through conventional chemistry.
  • the ester in C 15a may be reduced to an alcohol C18 in a suitable solvent such as THF or ether with a reducing agent such as DIBAL-H and conveniently carried out at temperatures from -100°C to 0°C.
  • the alcohol may be acylated to Compound C19 in a suitable solvent such as dichloromethane using an acyl halide or acid anhydride in the presence of a base such as triethyl amine (TEA).
  • TAA triethyl amine
  • the hydroxy group in C18 may also be converted to a good leaving group such as mesylate and displaced by a nucleophile such as cyanide, a thiol or an azide.
  • Reduction of the azide in compounds of Formula C20 to an amine C21 can be achieved by hydrogenation in the presence of a noble metal such as palladium or its oxide or Raney nickel in a protic solvent such as ethanol.
  • a noble metal such as palladium or its oxide or Raney nickel
  • a protic solvent such as ethanol.
  • the nitrile can be reduced to afford the homologous amine.
  • the amine of Formula C21 may be further elaborated to amides, ureas sulfonamides as defined by X through conventional chemistry.
  • the protecting group L may be removed through conventional chemistry.
  • a convenient method involves the addition reaction by an activated form of an alkyl, aryl, alkylaryl group, such as lithium reagent, Grignard reagents, and the like with a ketone of general formula C28, which is commercially available. Further derivatization of the resulting hydroxy group by acylation, sulfonylation, alkylation, and the like gives compounds as defined by Y or X through conventional chemistry. Removal of the benzyl protective group may be carried out under the usual conditions to give compounds of general formula C2b. Shown in Scheme C 16 is a general example of acylations.
  • a sulfide In cases where a sulfide is present in the molecule, it may be oxidized to a sulfoxide or to a sulfone with oxidizing agents such as sodium periodate, m-chloroperbenzoic acid or Oxone® in an solvent such as dichloromethane, alcohol or water or their mixtures.
  • oxidizing agents such as sodium periodate, m-chloroperbenzoic acid or Oxone® in an solvent such as dichloromethane, alcohol or water or their mixtures.
  • the compounds of the present invention may also be prepared from a variety of substituted natural and unnatural amino acids of formula D46. The preparation of many of these acids is described in
  • D46 amino acids D46 amino acids.
  • One of the common methods is to resolve amino or carboxyl protected intermediates by crystallization of salts derived from optically active acids or amines.
  • the amino group of carboxyl protected intermediates may be coupled to optically active acids by using chemistry described earlier. Separation of the individual diastereomers either by chromatographic techniques or by crystallization followed by hydrolysis of the chiral amide furnishes resolved amino acids.
  • amino protected intermediates may be converted to a mixture of chiral diastereomeric esters and amides. Separation of the mixture using methods described above and hydrolysis of the individual diastereomers provides (D) and (L) amino acids.
  • an enzymatic method to resolve N-acetyl derivatives of (DL)-amino acids has been reported by Whitesides and coworkers in J. Am. Chem. Soc. 1989, 111. 6354-6364.
  • Intermediates of formula D46 which are O-benzyl-(D)- serine derivatives D51 are conveniently prepared from suitably substituted benzyl halides and N-protected-(D)-serine D50.
  • the protecting group L is conveniently a BOC or a CBZ group.
  • Benzylation of D64 can be achieved by a number of methods well known in the literature including deprotonation with two equivalents of sodium hydride in an inert solvent such as DMF followed by treatment with one equivalent of a variety of benzyl halides (Synthesis 1989, 36) as shown in Scheme D15.
  • the 0-alkyl-(D)-serine derivatives may also be prepared using an alkylation protocol.
  • the growth hormone releasing compounds of Formula I are useful in vitro as unique tools for understanding how growth hormone secretion is regulated at the pituitary level. This includes use in the evaluation of many factors thought or known to influence growth hormone secretion such as age, sex, nutritional factors, glucose, amino acids, fatty acids, as well as fasting and non-fasting states. In addition, the compounds of this invention can be used in the evaluation of how other hormones modify growth hormone releasing activity. For example, it has already been established that somatostatin inhibits growth hormone release.
  • hormones that are important and in need of study as to their effect on growth hormone release include the gonadal hormones, e.g., testosterone, estradiol, and progesterone; the adrenal hormones, e.g., cortisol and other corticoids, epinephrine and norepinephrine; the pancreatic and gastrointestinal hormones, e.g., insulin, glucagon, gastrin, secretin; the vasoactive peptides, e.g., bombesin, the neurokinins; and the thyroid hormones, e.g., thyroxine and triiodothyronine.
  • gonadal hormones e.g., testosterone, estradiol, and progesterone
  • the adrenal hormones e.g., cortisol and other corticoids, epinephrine and norepinephrine
  • the pancreatic and gastrointestinal hormones e.g., insulin, glucagon,
  • the compounds of Formula I can also be employed to investigate the possible negative or positive feedback effects of some of the pituitary hormones, e.g., growth hormone and endorphin peptides, on the pituitary to modify growth hormone release.
  • some of the pituitary hormones e.g., growth hormone and endorphin peptides
  • endorphin peptides e.g., endorphin peptides
  • the compounds of Formula I may be administered to animals, including man, to release growth hormone in vivo.
  • the compounds can be administered to commercially important animals such as swine, cattle, sheep and the like to accelerate and increase their rate and extent of growth, to improve feed efficiency and to increase milk production in such animals.
  • these compounds can be administered to humans in vivo as a diagnostic tool to directly determine whether the pituitary is capable of releasing growth hormone.
  • the compounds of Formula I can be administered in vivo to children. Serum samples taken before and after such administration can be assayed for growth hormone. Comparison of the amounts of growth hormone in each of these samples would be a means for directly determining the ability of the patient's pituitary to release growth hormone.
  • the present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, at least one of the compounds of Formula I in association with a pharmaceutical carrier or diluent.
  • the active ingredient of the pharmaceutical compositions can comprise an anabolic agent in addition to at least one of the compounds of Formula I or another composition which exhibits a different activity, e.g., an antibiotic growth permittant or an agent to treat osteoporosis or in combination with a corticosteroid to minimize the catabolic side effects or with other pharmaceutically active materials wherein the combination enhances efficacy and minimizes side effects.
  • Growth promoting and anabolic agents include, but are not limited to TRH, diethylstilbesterol, estrogens, ⁇ -agonists, theophylline, anabolic steroids, enkephalins, E series prostaglandins, compounds disclosed in U.S. Patent No. 3,239,345, e.g., zeranol, and compounds disclosed in U.S. Patent No. 4,036,979, e.g., sulbenox or peptides disclosed in U.S. Patent No. 4,411,890.
  • a still further use of the growth hormone secretagogues of this invention is in combination with other growth hormone secretagogues such as the growth hormone releasing peptides GHRP- 6, GHRP-1 as described in U.S. Patent Nos. 4,411,890 and publications WO 89/07110, WO 89/07111 and B-HT920 as well as hexarelin and the newly discovered GHRP-2 as described in WO 93/04081 or growth hormone releasing hormone (GHRH, also designated GRF) and its analogs or growth hormone and its analogs or somatomedins including IGF-1 and IGF-2 or a- adrenergic aginists such as clonidine or serotonin 5HTID agonists such as sumitriptan or agents which inhibit somatostatin or its release such as physostigmine and pyridostigmine.
  • growth hormone secretagogues such as the growth hormone releasing peptides GHRP- 6, GHRP-1 as described in U.S
  • growth hormone As is well known to those skilled in the art, the known and potential uses of growth hormone are varied and multitudinous.
  • the administration of the compounds of this invention for purposes of stimulating the release of endogenous growth hormone can have the same effects or uses as growth hormone itself.
  • These varied uses of the present compounds thus may be summarized as follows: stimulating growth hormone release in elderly humans; treating growth hormone deficient adults; prevention of catabolic side effects of glucocorticoids; treatment of osteoporosis; stimulation of the immune system, acceleration of wound healing; accelerating bone fracture repair; treatment of growth retardation; treating acute or chronic renal failure or insufficiency; treatment of physiological short stature, including growth hormone deficient children; treating short stature associated with chronic illness; treatment of obesity and growth retardation associated with obesity; treating growth retardation associated with Prader-Willi syndrome and Turner's syndrome; accelerating the recovery and reducing hospitalization of burn patients or following major surgery such as gastrointestinal surgery; treatment of intrauterine growth retardation, and skeletal dysplasia, treatment of peripheral neuropathies; replacement
  • the instant compounds are useful for increasing feed efficiency, promoting growth, increasing milk production and improving the carcass quality of livestock.
  • the instant compounds are useful in the prevention or treatment of a condition selected from the group consisting of: osteoporosis; catabolic illness; immune deficiency, including that in individuals with a depressed T4/T8 cell ratio; hip fracture; musculoskeletal impairment in the elderly; growth hormone deficiency in adults or in children; obesity; cachexia and protein loss due to chronic illness such as AIDS or cancer; and treating patients recovering from major surgery, wounds or burns, in a patient in need thereof.
  • the therapeutic agents and the growth hormone secretagogues of this invention may be independently present in dose ranges from one one-hundredth to one times the dose levels which are effective when these compounds and secretagogues are used singly.
  • bisphosphonates for these utilities has been reviewed, for example, by Hamdy, N.A.T., Role of Bisphosphonates in Metabolic Bone Diseases, Trends in Endocrinol. Metab.. 4, 19-25 (1993).
  • Bisphosphonates with these utilities include alendronate, tiludronate, dimethyl- APD, risedronate, etidronate, YM-175, clodronate, pamidronate, and BM-210995.
  • oral daily dosage levels of the bisphosphonate of between 0.1 mg and 5 g and daily dosage levels of the growth hormone secretagogues of this invention of between 0.01 mg/kg to 20 mg/kg of body weight are administered to patients to obtain effective treatment of osteoporosis.
  • the compounds of this invention can be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant), nasal, vaginal, rectal, sublingual, or topical routes of administration and can be formulated in dosage forms appropriate for each route of administration.
  • parenteral e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant
  • nasal, vaginal, rectal, sublingual, or topical routes of administration and can be formulated in dosage forms appropriate for each route of administration.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules.
  • the active compound is admixed with at least one inert pharmaceutically acceptable carrier such as sucrose, lactose, or starch.
  • Such dosage forms can also comprise, as is normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate.
  • the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, the elixirs containing inert diluents commonly used in the art, such as water. Besides such inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.
  • Preparations according to this invention for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, or emulsions.
  • non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate.
  • Such dosage forms may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. They may be sterilized by, for example, filtration through a bacteria- retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions. They can also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
  • compositions for rectal or vaginal administration are preferably suppositories which may contain, in addition to the active substance, excipients such as cocoa butter or a suppository wax.
  • Compositions for nasal or sublingual administration are also prepared with standard excipients well known in the art.
  • the dosage of active ingredient in the compositions of this invention may be varied; however, it is necessary that the amount of the active ingredient be such that a suitable dosage form is obtained.
  • the selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment. Generally, dosage levels of between 0.0001 to 100 mg/kg. of body weight daily are administered to patients and animals, e.g., mammals, to obtain effective release of growth hormone.
  • Step A (DL -N-acetyl-2-amino-5-phenylpentanoic acid
  • the product above was suspended in 190 mL of 2.5 N NaOH in water and refluxed for two hours. The mixture was cooled to 0°C, and it was carefully neutralized with 6 N HC1 to pH2. The precipitate was collected using a sintered glass funnel and washed with a small amount of cold water and air dried. The solid was then suspended in 300 mL of water and refluxed for four hours. The solution was cooled and acidified to pHl and the solid was collected by filtration (15.3 g, 67%).
  • Step B (DVN-acetyl-2-amino-5-phenylpentanoic acid
  • Step C ( " D -N-t-Boc-2-amino-5-phenylpentanoic acid 0
  • the intermediate from step B (4.2 g, 17.8 mmol) was suspended in 2 N HCl (100 mL) and refluxed for two hours.
  • the reaction mixture was evaporated in vacuo to remove water and hydrochloric acid to yield a white solid.
  • Step A (dl)-Pipecolinic acid, benzyl ester
  • step B A suspension of the product from Example A4, step B (5.30 g) and 10% palladium on carbon (270 mg) in ethanol (100 mL) was stirred under a hydrogen balloon for 3 hours. The reaction mixmre was filtered through celite, evaporated to give the acid ( 4.48g).
  • Step B 4-Phenylpyridine-2-carboxylic acid A solution of the product from the previous step (25 g) in
  • Example A9 step A Prepared according to the procedure in Example A9 step A from the intermediate from the previous step (27 g).
  • the crude reaction product was purified by a Si02 flash column eluting with 20-40% ethyl acetate in hexane to give 5-benzyl-2-cyanopyridine (3.0g, 10%) and 3- benzyl-2-cyanopyridine (24.2 g, 85%).
  • Step C 3-Benzylpyridine-2-carboxylic acid hydrochloride A solution of 3-benzyl-2-cyanopyridine (19.1 g) in concentrated hydrochloric acid (50 mL) and water (50 mL) was refluxed for two days. The resulting solution was evaporated to give a solid (30.1 g 100%, which contains an equal molar amount of ammonium chloride).
  • Step A Diethyl piperidine-2.3-(cis)-dicarboxylate Hydrogen chloride gas was bubbled into ethanol (400 mL) until 22 g was absorbed. Pyridine-2,3-dicarboxylic acid (100 g) was dissolved in this solution and the resulting mixture was refluxed overnight. The reaction mixmre was divided into two portions and each was shaken with Pt02 (1.4 g) in Parr shakers under 40 psi of hydrogen for 8 hours. The reaction mixture was combined and filtered through celite and washed with plenty of ethanol. Evaporation gave a gray solid which was washed with ethyl acetate to give a white solid after filtration (74.8 g)
  • the intermediate was prepared by epimerization of its all cis isomer with KHMDS in THF.
  • Step A Diethyl N-Boc-piperidine-(cis)-2.3-dicarboxylate
  • the reaction was quenched with 75 mL of water and oxygen gas was bubbled in for 3h.
  • the organic layer was washed with water, brine (200 mL), dried over Na2S ⁇ 4, filtered, and evaporated.
  • the reaction was quenched with 75 mL of water and oxygen gas was bubbled in for 3h.
  • the organic layer was washed with water, brine (200 mL), dried over Na2S ⁇ 4, filtered, and evaporated. Flash chromatography of the residue with hexane- ethylacetate (1:1) as the eluent gave the desired product.
  • Example B 1 The Pt ⁇ 2 reduction of the phenyl-piperidine intermediate prepared in Step A, Example B 1 was attempted in different solvents like ethanol and methanol in the presence and absence of cone. HCl. Transesterification as well as unselective reduction of the pyridine was observed. Several of these reactions were combined and treated with excess di-t-butylcarbonate in CH2CI2 and triethylamine. Approximately 5.0 g of the crude material thereby obtained after acid work-up was treated with 1.6 g of NaOH in 100 mL of methanol and 10 mL of water for 2h. The reaction mixture was diluted with water and washed with ether. The aqueous layer was acidified with 0.50N HCl till acidic and extracted with CHCI3.
  • Example B7 To a solution of 0.19 g of the intermediate from Step C, Example B7 in 3 mL of dioxane was added 50 mg of 10% Pd/C and hydrogenated under H2 balloon for 3h. The reaction was slow so about 50 mg of 20% Pd(OH)2/C was added and hydrogenated overnight. The catalyst was filtered off through a pad of celite and washed with dioxane. Evaporation of the filtrate gave the title compound as a pink solid.
  • Step A- 1
  • Step C The intermediate obtained from Step C was dissolved in 3 ml of methanol and hydrogenated over Pd(OH)2/C at one atmosphere for an hour (monitored by TLC). The mixmre was filtered through Celite and the filtrate concentrated under vacuum. The residue was acidified with HCl in ether to give a white precipitate (dl, 40 mg).
  • the title compound was prepared from the compound made in Step A by treating it with a saturated solution of HCl(gas) in ethyl acetate for 30min. at RT. Ether was added and the precipitate was filtered and dried.
  • iH NMR 400 MHz, CD3OD mixture of rotamers: 8.10 (t, IH), 7.78 (dd, IH), 7.50-7.00 (m, 8H), 4.90 (m, IH), 4.55 (d, IH), 3.94 and 3.90 (2 doublets, IH), 3.80-3.60 (m, IH), 3.05 (dt, IH), 2.70-2.50 (m, 4H), 1.90- 1.50 (m, 6H), 1.55 (s, 3H), 1.50 (s, 3H), 1.40 (m, IH).
  • Step A-l 1.0 g, 3.02 mmole
  • 4N sodium hydroxide 4 ml
  • the reaction was stirred at room temperature for 16 hours and evaporated in vacuo.
  • the residue was diluted with water and acidified with 0.5N hydrochloric acid and then exacted with ether.
  • the orgamc layer was dried over sodium sulfate, filtered and concentrated.
  • the crude residue was dissolved in methanol and hydrogenated over Pd(OH)2 at one atmosphere for 16 hours. The mixture was filtered through Celite and the filtrate concentrated under vacuum.
  • Step A-l 950 mg, 2.87 mmole
  • diisobutylaluminum hydride 1.0 N in methylene chloride, 8 ml, 8.0 mmole
  • the mixture was stirred at 0°C for 1 hour and then slowly warmed to room temperature.
  • the mixture was quenched with IN sodium hydroxide, and extracted with ether (3X).
  • the organic layer was dried over sodium sulfate, filtered and concentrated.
  • Step A To intermediate prepared from Example B12, Step A (87 mg) there was added 1 ml of TFA. After 10 minutes, the mixture was concentrated and azeotroped with toluene (3X). The residue was dissolved in ethyl acetate and washed with sodium bicarbonate. The organic layer was concentrated. To the residue in 3 ml of methylene chloride there was added N-BOC-(2R)-amino-5-phenylpentanoic acid (70 mg), EDC (55 mg), and HOBt (35 mg). After a couple of hours, the reaction was poured into water and extracted with methylene chloride,, dried over sodium sulfate, filtered and concentrated. Step B:
  • the desired d2 compound (40 mg) was prepared from the more polar diastereomer obtained in Example B23, Step B (53 mg) by the procedure described in Example B23, Step C.
  • iH NMR 400 MHz, CD3OD mixture of rotamers: 7.23 (m, 10 H), 4.91 (m, 1 H), 4.75 (m, 1 H), 4.03 (m, 1 H), 3.81 (m, 2 H), 3.45 (m, 1/2 H), 3.26-2.96 (m, 4 H), 2.71 (m, 2 1/2 H), 2.40 (m, 1 H), 1.90-1.64 (m, 4 H), 1.63 (s, 2 H), 1.61 (s, 3 H), 1.59 (s, 3 H), 0.93 (t, 7 Hz, 3 H).
  • FAB-MS 494.3 (M+l).
  • EXAMPLE B25 (cis. dl+d2)
  • Example B30 To 0.90g of the intermediate prepared in Step A Example B30 in 5mL of methanol was added 0. lOg of 20% palladium hydroxide and hydrogenated at atmospheric pressure overnight. The catalyst was filtered off through a pad of celite and washed with methanol. The filtrate was concentrated and the residue was dried under vacuum to provide the acid as a colorless foam that was used without purification.
  • Example B2 The compounds described in Table B2 were prepared from intermediate synthesized in Step A of Example B31 by taking advantage of chemistry used to prepare the title compound in Example B5.
  • Other amines as depicted below were used in place of ethanolamine and the final deprotection was carried in ethyl acetate and dry hydrochloric acid. Ether was generally used to precipitate the hydrochloride salt.
  • This intermediate was prepared in an analogous manner to the BOC material prepared in Step B of Example B38.
  • the isocyanate intermediate prepared (0.20g) in Step A of Example B42 was refluxed in 5mL of 6N aqueous HCl overnight.
  • the reaction mixture was washed with ether and the ether layer was discarded.
  • the combined organics were washed with brine, dried over K2CO3 and concentrated.
  • This crude amine was converted to the methanesulfonamide by treating it with methanesulfonyl chloride and triethylamine in dichloromethane. After standard work-up the CBZ group was removed by hydrogenation and elaborated to the title compound as discussed previously.
  • This compound was prepared in an analogous manner to the ° protected piperidine acid compound synthesized in Step A of Example B37.
  • Step B To a solution of 0.30g of the imino-ether intermediate prepared in Step B of Example B40 in lOmL of ethanol was added 0.124g of dihydroxyacetone and heated at 60°C under an ammonia atmosphere in a bomb for 16h. The reaction was cooled to room temperamre and the solvent was evaporated. The residue was purified by flash chromatography to give 0J29g of the desired product that was still contaminated with other impurities.
  • Step A The intermediate prepared in Step A was elaborated to the title compound after removal of the CBZ protecting group, coupling with Intermediate 3, purification, and a final deprotection with the EtOAc/HCl protocol described earlier.
  • iH NMR 400 MHz, CD3OD mixture of rotamers: 8.18 (2 triplets, IH), 7.30 (s, IH), 7.30-7.00 (m, 9H), 4.90 (m, IH), 4.56-4.55 (singlet overlapping a doublet, 3H), 4.05-3.95 (2 doublets, IH), 3.30-2.95 (m, 4H), 2.95-2.60 (m, 5H), 1.90-1.65 (m, 7H), 1.63 (s, 3H), 1.60 (s, 3H), 1.45 (m, IH).
  • the crude alcohol was dissolved in 30mL of CH2CI2 and 1.3mL of triethylamine and 1.4g of di-t- butylcarbonate was added at 0°C and then stirred at RT for 2h.
  • the reaction was poured into saturated NaHC03 solution and extracted with CH2CI2.
  • the combined organics were washed with 0.50N HCl, brine, dried over Na2S ⁇ 4 and concentrated. This material was purified by flash chromatography with hexane-acetone (5:1) as the eluent.

Abstract

L'invention concerne certains composés de pipéridine, de pyrrolidine, et d'hexahydro-1H-azépine de formule structurale (I) dans laquelle R1, R3, R4, R5, A, W, X, Y et n sont définis dans la description. Ces composés favorisent la libération de l'hormone de croissance chez les humains et les animaux. Cette propriété peut être utilisée pour favoriser la croissance d'animaux destinés à l'alimentation et augmenter la production de produits de viande comestibles, et, chez les humains, pour traiter des états physiologiques ou médicaux caractérisés par une insuffisance de sécrétion de l'hormone de croissance telle que l'insuffisance staturale chez l'enfant, et traiter des états médicaux pouvant être améliorés par les effets anabolisants de l'hormone de croissance. L'invention porte également sur des compositions libérant l'hormone de croissance dans lesquelles lesdits composés sont utilisés comme principes actifs.
EP95902467A 1993-11-09 1994-11-07 Piperidines, pyrrolidines et hexahydro-1h-azepines favorisant la liberation de l'hormone de croissance Withdrawn EP0739204A4 (fr)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US149441 1980-05-13
US14944193A 1993-11-09 1993-11-09
US16514993A 1993-12-10 1993-12-10
US165149 1993-12-10
US17344993A 1993-12-23 1993-12-23
US173449 1993-12-23
US08/323,998 US5492920A (en) 1993-12-10 1994-10-17 Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
US323994 1994-10-17
US323988 1994-10-17
US08/323,994 US5494919A (en) 1993-11-09 1994-10-17 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US08/323,988 US5492916A (en) 1993-12-23 1994-10-17 Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US323998 1994-10-17
PCT/US1994/012816 WO1995013069A1 (fr) 1993-11-09 1994-11-07 Piperidines, pyrrolidines et hexahydro-1h-azepines favorisant la liberation de l'hormone de croissance

Publications (2)

Publication Number Publication Date
EP0739204A1 EP0739204A1 (fr) 1996-10-30
EP0739204A4 true EP0739204A4 (fr) 2000-03-15

Family

ID=27558364

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95902467A Withdrawn EP0739204A4 (fr) 1993-11-09 1994-11-07 Piperidines, pyrrolidines et hexahydro-1h-azepines favorisant la liberation de l'hormone de croissance

Country Status (16)

Country Link
EP (1) EP0739204A4 (fr)
JP (1) JPH10506091A (fr)
KR (1) KR960705808A (fr)
CN (1) CN1174504A (fr)
AU (1) AU1172995A (fr)
BG (1) BG100555A (fr)
BR (1) BR9408019A (fr)
CA (1) CA2175218A1 (fr)
CZ (1) CZ134296A3 (fr)
FI (1) FI961951A0 (fr)
HU (1) HUT74733A (fr)
LV (1) LV11525B (fr)
NO (1) NO961865L (fr)
PL (1) PL322706A1 (fr)
SK (1) SK56296A3 (fr)
WO (1) WO1995013069A1 (fr)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5721251A (en) * 1993-12-10 1998-02-24 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
US5721250A (en) * 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5767118A (en) * 1994-10-26 1998-06-16 Merck & Co., Inc. 4-Heterocyclic peperidines promote release of growth hormone
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
US20020111461A1 (en) 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
US5731317A (en) * 1995-03-10 1998-03-24 Merck & Co., Inc. Bridged piperidines promote release of growth hormone
US5559128A (en) * 1995-04-18 1996-09-24 Merck & Co., Inc. 3-substituted piperidines promote release of growth hormone
WO1996035713A1 (fr) * 1995-05-08 1996-11-14 Pfizer, Inc. Dipeptides stimulant la liberation de l'hormone de croissance
US5620993A (en) * 1995-06-07 1997-04-15 Merck & Co., Inc. Alpha-1a adrenergic receptor antagonists
WO1997022004A1 (fr) 1995-12-13 1997-06-19 Merck & Co., Inc. Dosage des recepteurs secretagogues d'hormones de croissance
US6531314B1 (en) 1996-12-10 2003-03-11 Merck & Co., Inc. Growth hormone secretagogue receptor family
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
GB9526645D0 (en) * 1995-12-28 1996-02-28 Chiroscience Ltd Stereoselective synthesis
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
DE69837264T2 (de) * 1997-06-25 2008-01-31 Pfizer Inc. Dipeptidverbindungen, die Wachstumshormon-Sekretagoga sind
UA53716C2 (uk) * 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
US6339087B1 (en) 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
US6303620B1 (en) 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
AU757217B2 (en) * 1998-05-11 2003-02-06 Helsinn Healthcare Sa Compounds with growth hormone releasing properties
DZ2815A1 (fr) * 1998-06-12 2003-12-01 Smithkline Beecham Corp Inhibiteurs de protéase.
US6682908B1 (en) 1998-07-10 2004-01-27 Merck & Co., Inc. Mouse growth hormone secretagogue receptor
CA2333857A1 (fr) 1998-07-13 2000-01-20 Merck & Co., Inc. Recepteurs et acides nucleiques en rapport avec un secretagogue d'hormone de croissance
US6645726B1 (en) 1998-08-10 2003-11-11 Merck & Co., Inc. Canine growth hormone secretagogue receptor
US6468974B1 (en) 1998-08-14 2002-10-22 The Administrators Of The Tulane Educational Fund Compounds having growth hormone releasing activity
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
CA2362290A1 (fr) 1999-02-18 2000-08-24 Kaken Pharmaceutical Co., Ltd. Nouveaux derives amide secretagogues de l'hormone de croissance
JP2002523368A (ja) * 1999-02-19 2002-07-30 イーライ・リリー・アンド・カンパニー 成長ホルモン分泌促進薬
US6541634B2 (en) 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
BR0009043A (pt) 1999-03-15 2002-01-08 Axys Pharm Inc Composto, composição farmacêutica, e, método de tratar uma doença em um animal em que a atividade da cisteìna protease contribui para a patologia e/ou sintomatologia da doença
US6110949A (en) * 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6172081B1 (en) 1999-06-24 2001-01-09 Novartis Ag Tetrahydroisoquinoline 3-carboxamide derivatives
US6617340B1 (en) 1999-07-29 2003-09-09 Novartis Ag N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6784200B2 (en) 2000-10-13 2004-08-31 Bristol-Myers Squibb Pharma Company Bicyclic and tricyclic amines as modulators of chemokine receptor activity
AU1201101A (en) 1999-10-15 2001-04-30 Du Pont Pharmaceuticals Company Bicyclic and tricyclic amines as modulators of chemokine receptor activity
JP2003512349A (ja) 1999-10-15 2003-04-02 デュポン ファーマシューティカルズ カンパニー ケモカイン受容体活性のモジュレーターとしてのベンジルシクロアルキルアミン
UA73530C2 (uk) * 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
ES2252230T3 (es) 2000-05-11 2006-05-16 Bristol-Myers Squibb Company Analogos de tetrahidroisoquinolina utiles como secretores de la hormona del crecimiento.
ATE446758T1 (de) 2000-05-31 2009-11-15 Pfizer Prod Inc Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
US6638950B2 (en) 2000-06-21 2003-10-28 Bristol-Myers Squibb Pharma Company Piperidine amides as modulators of chemokine receptor activity
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
JP2004523506A (ja) 2000-12-22 2004-08-05 アクシス・ファーマシューティカルズ・インコーポレイテッド カテプシン阻害剤としての新規な化合物と組成物
DE10105041A1 (de) * 2001-02-05 2002-08-14 Tell Pharm Ag Hergiswil Tripeptide und Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten
MXPA04002282A (es) 2001-09-14 2005-03-07 Axis Pharmaceutical Inc Nuevos compuestos y preparaciones como inhibidores de la catepsina.
AU2002326948A1 (en) 2001-09-18 2003-04-01 Bristol-Myers Squibb Company Piperizinones as modulators of chemokine receptor activity
WO2003026649A1 (fr) * 2001-09-27 2003-04-03 Applied Research Systems Ars Holding N.V. Methodes pouvant augmenter des concentrations en testosterone endogene
AU2002357692A1 (en) 2001-11-09 2003-05-26 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
KR20050044497A (ko) 2001-11-14 2005-05-12 아벤티스 파마슈티칼스 인크. 올리고펩티드 및 카텝신 ｓ 억제제로서 이를 포함하는조성물
US7153822B2 (en) 2002-01-29 2006-12-26 Wyeth Compositions and methods for modulating connexin hemichannels
TW200409630A (en) 2002-09-12 2004-06-16 Bristol Myers Squibb Co N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2004028530A1 (fr) 2002-09-26 2004-04-08 Bristol-Myers Squibb Company Amines heterocycliques n-substituees, utilisees comme modulateurs de l'activite des recepteurs des chimiokines
US7659305B2 (en) 2002-10-31 2010-02-09 Pfizer Inc. Therapeutic proline derivatives
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
CN103772483A (zh) * 2004-06-29 2014-05-07 赫尔辛医疗股份公司 （3r）－1－（2－甲基丙氨酰－d－色氨酰）－3－（苯甲基）－3－哌啶羧酸1,2,2－三甲基酰肼的晶形
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
EP1760076A1 (fr) 2005-09-02 2007-03-07 Ferring B.V. Inhibiteur de FAP
PL1966130T3 (pl) 2005-12-23 2014-05-30 Zealand Pharma As Zmodyfikowane związki mimetyczne lizyny
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
EP1897956A1 (fr) 2006-09-06 2008-03-12 Lonza AG Procédé de préparation d'amines optiquement actives par résolution optique en utilisant d'une oméga-transaminase bactérienne
EP2468724B1 (fr) 2006-12-21 2015-11-18 Zealand Pharma A/S Synthèse de composés de pyrrolidine
EP2118080B1 (fr) 2007-02-09 2016-08-31 Ocera Therapeutics, Inc. Modulateurs macrocycliques du récepteur de la ghréline et leurs procédés d'utilisation
EP2155769B1 (fr) 2007-05-04 2012-06-27 Katholieke Universiteit Leuven KU Leuven Research & Development Protection contre la dégénérescence tissulaire
JP2009256298A (ja) * 2008-03-26 2009-11-05 Sumitomo Chemical Co Ltd ピペリジン−３−イルカーバメート化合物の光学分割方法およびその中間体
WO2013190520A2 (fr) 2012-06-22 2013-12-27 The General Hospital Corporation Agents de libération de gh dans le traitement d'une sténose vasculaire et d'états associés
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
CN106572997A (zh) 2014-05-30 2017-04-19 辉瑞公司 作为选择性雄激素受体调节剂的腈衍生物
MX2017001408A (es) * 2014-08-05 2017-05-10 Raqualia Pharma Inc Derivados de serina como agonistas del receptor de grelina.
WO2017075535A1 (fr) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Méthodes de traitement de troubles neurodégénératifs
HU231150B1 (hu) 2017-03-13 2021-03-29 Richter Gedeon Nyrt Eljárás racém 3-alkilpiperidin-3-karbonsav-etil-észterek optikai izomerjeinek elválasztására
EP3618847B1 (fr) 2017-05-05 2021-04-07 Zealand Pharma A/S Modulateurs de la communication intercellulaire par les jonctions lacunaires et leur utilisation pour le traitement d'une maladie oculaire diabétique
BR112020016256A2 (pt) 2018-02-21 2020-12-15 AI Therapeutics, Inc. Terapia de combinação com apilimod e agentes gluta-matérgicos
CN112204007B (zh) * 2018-06-01 2023-06-20 施万生物制药研发Ip有限责任公司 制备2-(1-(叔丁氧基羰基)哌啶-4-基)苯甲酸的方法
WO2023275715A1 (fr) 2021-06-30 2023-01-05 Pfizer Inc. Métabolites de modulateurs sélectifs du récepteur des androgènes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0144230A2 (fr) * 1983-12-07 1985-06-12 Pfizer Limited Promoteurs de croissance pour animaux
EP0513974A1 (fr) * 1991-03-20 1992-11-19 Merck & Co. Inc. Nouveaux lactames benzo-condensés favorisant la libération de l'hormone de croissance

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) * 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
HU180925B (en) * 1979-06-28 1983-05-30 Richter Gedeon Vegyeszet Process for producing tripeptide-amides trh-analogues,effectives on the central nerve systhem
US5036045A (en) * 1985-09-12 1991-07-30 The University Of Virginia Alumni Patents Foundation Method for increasing growth hormone secretion
US4782139A (en) * 1985-10-28 1988-11-01 Eli Lilly And Company Selective chemical removal of a protein amino-terminal residue
US4997825A (en) * 1986-12-22 1991-03-05 Eli Lilly And Company Synergistic treatment method
US5162302A (en) * 1988-03-18 1992-11-10 University Of Delaware Endocrine manipulation to improve body composition of poultry
US5084442A (en) * 1988-09-06 1992-01-28 Hoffmann-La Roche Inc. Cyclic growth hormone releasing factor analogs and method for the manufacture thereof
US5137872A (en) * 1989-09-18 1992-08-11 Pitman-Moore, Inc. Growth hormone-releasing factor analogs
IE912345A1 (en) * 1990-08-03 1992-02-12 Pharmacia Ab Treatment of human lactation failure
JP2557779B2 (ja) * 1990-11-26 1996-11-27 アール． レッカー，ロバート ２成分型骨粗鬆症用薬剤
JP3098082B2 (ja) * 1991-12-12 2000-10-10 三井化学株式会社 アミノ基含有化合物の製造方法
US5366965A (en) * 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
US5284841A (en) * 1993-02-04 1994-02-08 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0144230A2 (fr) * 1983-12-07 1985-06-12 Pfizer Limited Promoteurs de croissance pour animaux
EP0513974A1 (fr) * 1991-03-20 1992-11-19 Merck & Co. Inc. Nouveaux lactames benzo-condensés favorisant la libération de l'hormone de croissance

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
H.SAKAMOTO ET AL.: "Chymotrypsin Inhibition by Dipeptide Esters, Phenylpepridide and Phenylpeperazides", PEPTIDE CHEMISTRY, vol. 27, 1989, pages 375 - 8, XP002127636 *
See also references of WO9513069A1 *

Also Published As

Publication number Publication date
CA2175218A1 (fr) 1995-05-18
EP0739204A1 (fr) 1996-10-30
HU9601230D0 (en) 1996-07-29
SK56296A3 (en) 1997-02-05
BG100555A (bg) 1996-10-31
CZ134296A3 (en) 1996-12-11
BR9408019A (pt) 1997-08-26
WO1995013069A1 (fr) 1995-05-18
KR960705808A (ko) 1996-11-08
FI961951A (fi) 1996-05-08
PL322706A1 (en) 1998-02-16
JPH10506091A (ja) 1998-06-16
LV11525A (lv) 1996-10-20
FI961951A0 (fi) 1996-05-08
NO961865D0 (no) 1996-05-08
CN1174504A (zh) 1998-02-25
AU1172995A (en) 1995-05-29
LV11525B (en) 1997-02-20
NO961865L (no) 1996-07-08
HUT74733A (en) 1997-02-28

Similar Documents

Publication Publication Date Title
EP0739204A4 (fr) Piperidines, pyrrolidines et hexahydro-1h-azepines favorisant la liberation de l'hormone de croissance
AU684878B2 (en) Compounds and the use thereof to promote the release of growth hormone(s)
US5494919A (en) 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5492920A (en) Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
US5721251A (en) Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
EP0615977B1 (fr) Spiro piperidines et ses homologues favorisants la libération de l'hormone de croissance
US5783582A (en) Piperidines and hexahydro-1H-azepines spiro substituted at the 4-position promote release of growth hormone
WO1996032943A1 (fr) Piperidines substituees en position 3 favorisant la secretion d'hormone de croissance
US5777112A (en) Piperazine compounds promote release of growth hormone
US5804578A (en) Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
WO1998010653A1 (fr) Piperidines, pyrrolidines et hexahydro-1h-azepines favorisant la secretion d'hormone de croissance
US5767118A (en) 4-Heterocyclic peperidines promote release of growth hormone
WO1994019367A1 (fr) Spiro piperidines et composes homologues favorisant la liberation de l'hormone de croissance
CZ302095A3 (en) Novel peptide derivatives
WO1997034604A1 (fr) 4-spiroindoline piperidines favorisant la liberation de l'hormone de croissance
WO1997036873A1 (fr) Piperidines, pyrrolidines et hexahydro-1h-azepines declenchant la liberation de l'hormone de croissance
US5880125A (en) 4-spiroindoline piperidines promote release of growth hormone
US5965565A (en) Piperidines promote release of growth hormone
GB2298647A (en) Bridged piperidines promoting release of growth hormone
JP2509147B2 (ja) 成長ホルモンの放出を亢進させるスピロピペリジン及び同族体
WO1997011697A1 (fr) Piperidines et pyrroolidines de 3-spirolactame, 3-spiroamino, 3-spirolactone et 3-spirobenzopyran permettant de promouvoir la liberation de l'hormone de croissance
WO1998025897A1 (fr) Piperidines, pyrrolidines et hexahydro-1h azepines favorisent la liberation de l'hormone de croissance
EP1200432B1 (fr) Amido-spiropiperidines favorisant la liberation de l'hormone de croissance

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960610

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07D 401/02 A, 7C 07D 401/14 B, 7C 07D 409/02 B, 7C 07K 5/06 B, 7C 07D 453/02 B, 7C 07K 5/02 B, 7C 07K 5/08 B

A4 Supplementary search report drawn up and despatched

Effective date: 20000128

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020601